Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Friday 15 October, 2010

Lifeline Scientific

Director/PDMR Shareholding

RNS Number : 4374U
Lifeline Scientific, Inc
15 October 2010
 



 

 

Lifeline Scientific, Inc.

 

("Lifeline" or the "Company")

 

 

Exercise of Warrants

 

Lifeline Scientific, the medical technology company focused on commercialising its advanced organ preservation and transport systems, designed to address the global challenge of human donor organ shortages, announces that on the 14 October 2010, Andrew Clark, Senior Independent Director, exercised 21,666 warrants each for one common share at £1.95 per warrant.  Following the exercise of these warrants Andrew Clark holds a total of 129,999 common shares in the Company representing 0.7 per cent. of the common shares in issue.

 

Application has been made for the admission of the 21,666 shares to trading on the AIM market. Admission is expected to occur on 21 October 2010.

 

Following today's application, Lifeline has 17,604,139 common shares in issue and each share has the right to one vote.  Therefore for the purposes of the FSA Disclosure and Transparency Rules the total number of voting rights in the Company is 17,604,139.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the FSA's Disclsoure and Transparency Rules. 

 

Following today's application, 6,908,157 common shares remain subject to Regulation S restrictions and are held in certificated form only.  These common shares subject to Regulation S restrictions are traded under ISIN number USU529641008.

 

The remaining 10,695,982 common shares have had the Regulation S restrictions lifted and are held in uncertificated form trading under ISIN number US53223V1017.

 

 

Enquiries:

 

Lifeline Scientific, Inc.

+1 847 824 2420

David Kravitz, CEO


Seymour Pierce

+44 (0)20 7107 8000

Sarah Jacobs / Freddy Crossley


Financial Dynamics

+44 (0)20 7831 3113

Ben Brewerton / John Dineen


 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSQZLFFBBFFFBF